2025-2031 Global Premature Ovarian Failure Cure Industry Research & Trends Analysis Report- YH Research

Home > Reports >Medical Care > 2025-2031 Global Premature Ovarian Failure Cure Industry Research & Trends Analysis Report

2025-2031 Global Premature Ovarian Failure Cure Industry Research & Trends Analysis Report

Publication Date: 2025-11-19
Report Id: 2806929
Industry: Medical Care
Report Page: 125
Chart: 116

PDF Download

Publication Date: 2025-11-19
Report Id: 2806929
Industry: Medical Care
Report Page: 125
Chart: 116

PDF Download

A research report provider that focuses on identifying industry pain points and solving core problems for companies！

Table of Contents
Description
Table of Figures
Need a Quote?

1 Market Overview
1.1 Product Overview and Scope of Premature Ovarian Failure Cure
1.2 Global Premature Ovarian Failure Cure Market Size and Forecast
1.3 China Premature Ovarian Failure Cure Market Size and Forecast
1.4 China Percentage in Global Market
1.4.1 By Revenue, China Premature Ovarian Failure Cure Share in Global Market, 2020-2031
1.4.2 Premature Ovarian Failure Cure Market Size: China VS Global, 2020-2031
1.5 Premature Ovarian Failure Cure Market Dynamics
1.5.1 Premature Ovarian Failure Cure Market Drivers
1.5.2 Premature Ovarian Failure Cure Market Restraints
1.5.3 Premature Ovarian Failure Cure Industry Trends
1.5.4 Premature Ovarian Failure Cure Industry Policy

2 Competitive Landscape by Company
2.1 Global Premature Ovarian Failure Cure Revenue by Company, 2020-2025
2.2 Global Premature Ovarian Failure Cure Participants, Market Position (Tier 1, Tier 2, and Tier 3)
2.3 Global Premature Ovarian Failure Cure Concentration Ratio
2.4 Global Premature Ovarian Failure Cure Mergers & Acquisitions, Expansion Plans
2.5 Global Premature Ovarian Failure Cure Manufacturers Product Type
2.6 Global Geographic Distribution of Premature Ovarian Failure Cure Companies

3 China Competitive Situation by Company
3.1 China Premature Ovarian Failure Cure Revenue by Company, 2020-2025
3.2 China Premature Ovarian Failure Cure Premature Ovarian Failure Cure Participants, Market Position (Tier 1, Tier 2, and Tier 3)
3.3 China Premature Ovarian Failure Cure Market, Revenue Percentage of Local Players VS Foreign Players (2020-2031)

4 Industry Chain Analysis
4.1 Premature Ovarian Failure Cure Industry Chain
4.2 Premature Ovarian Failure Cure Upstream Analysis
4.3 Premature Ovarian Failure Cure Midstream Analysis
4.4 Premature Ovarian Failure Cure Downstream Analysis

5 Sights by Type
5.1 Premature Ovarian Failure Cure Classification
5.1.1 Hormone Replacement Therapy (HRT)
5.1.2 Calcium and Vitamin D Supplements
5.1.3 In Vitro Fertilization (IVF)
5.1.4 Stem Cell Therapy
5.1.5 Others
5.2 by Type, Global Premature Ovarian Failure Cure Market Size & CAGR, 2020 VS 2024 VS 2031
5.3 by Type, Global Premature Ovarian Failure Cure Market Size, 2020-2031

6 Sights by Application
6.1 Premature Ovarian Failure Cure Segment by Application
6.1.1 Less than 20 Years Old
6.1.2 20 to 30 Years Old
6.1.3 30 to 45 Years Old
6.1.4 45 Years Old and Older
6.2 by Application, Global Premature Ovarian Failure Cure Market Size & CAGR, 2020 VS 2024 VS 2031
6.3 by Application, Global Premature Ovarian Failure Cure Market Size, 2020-2031

7 Sights by Region
7.1 By Region, Global Premature Ovarian Failure Cure Market Size, 2020 VS 2024 VS 2031
7.2 By Region, Global Premature Ovarian Failure Cure Market Size, 2020-2031
7.3 North America
7.3.1 North America Premature Ovarian Failure Cure Market Size & Forecasts, 2020-2031
7.3.2 By Country, North America Premature Ovarian Failure Cure Market Size Market Share
7.4 Europe
7.4.1 Europe Premature Ovarian Failure Cure Market Size & Forecasts, 2020-2031
7.4.2 By Country, Europe Premature Ovarian Failure Cure Market Size Market Share
7.5 Asia Pacific
7.5.1 Asia Pacific Premature Ovarian Failure Cure Market Size & Forecasts, 2020-2031
7.5.2 By Country/Region, Asia Pacific Premature Ovarian Failure Cure Market Size Market Share
7.6 South America
7.6.1 South America Premature Ovarian Failure Cure Market Size & Forecasts, 2020-2031
7.6.2 By Country, South America Premature Ovarian Failure Cure Market Size Market Share
7.7 Middle East & Africa

8 Sights by Country Level
8.1 By Country, Global Premature Ovarian Failure Cure Market Size & CAGR，2020 VS 2024 VS 2031
8.2 By Country, Global Premature Ovarian Failure Cure Market Size, 2020-2031
8.3 United States
8.3.1 United States Premature Ovarian Failure Cure Market Size, 2020-2031
8.3.2 By Company, United States Premature Ovarian Failure Cure Revenue Market Share, 2024
8.3.3 by Type, United States Premature Ovarian Failure Cure Revenue Market Share, 2024 VS 2031
8.3.4 by Application, United States Premature Ovarian Failure Cure Revenue Market Share, 2024 VS 2031
8.4 Europe
8.4.1 Europe Premature Ovarian Failure Cure Market Size, 2020-2031
8.4.2 By Company, Europe Premature Ovarian Failure Cure Revenue Market Share, 2024
8.4.3 by Type, Europe Premature Ovarian Failure Cure Revenue Market Share, 2024 VS 2031
8.4.4 by Application, Europe Premature Ovarian Failure Cure Revenue Market Share, 2024 VS 2031
8.5 China
8.5.1 China Premature Ovarian Failure Cure Market Size, 2020-2031
8.5.2 By Company, China Premature Ovarian Failure Cure Revenue Market Share, 2024
8.5.3 by Type, China Premature Ovarian Failure Cure Revenue Market Share, 2024 VS 2031
8.5.4 by Application, China Premature Ovarian Failure Cure Revenue Market Share, 2024 VS 2031
8.6 Japan
8.6.1 Japan Premature Ovarian Failure Cure Market Size, 2020-2031
8.6.2 By Company, Japan Premature Ovarian Failure Cure Revenue Market Share, 2024
8.6.3 by Type, Japan Premature Ovarian Failure Cure Revenue Market Share, 2024 VS 2031
8.6.4 by Application, Japan Premature Ovarian Failure Cure Revenue Market Share, 2024 VS 2031
8.7 South Korea
8.7.1 South Korea Premature Ovarian Failure Cure Market Size, 2020-2031
8.7.2 By Company, South Korea Premature Ovarian Failure Cure Revenue Market Share, 2024
8.7.3 by Type, South Korea Premature Ovarian Failure Cure Revenue Market Share, 2024 VS 2031
8.7.4 by Application, South Korea Premature Ovarian Failure Cure Revenue Market Share, 2024 VS 2031
8.8 Southeast Asia
8.8.1 Southeast Asia Premature Ovarian Failure Cure Market Size, 2020-2031
8.8.2 By Company, Southeast Asia Premature Ovarian Failure Cure Revenue Market Share, 2024
8.8.3 by Type, Southeast Asia Premature Ovarian Failure Cure Revenue Market Share, 2024 VS 2031
8.8.4 by Application, Southeast Asia Premature Ovarian Failure Cure Revenue Market Share, 2024 VS 2031
8.9 India
8.9.1 India Premature Ovarian Failure Cure Market Size, 2020-2031
8.9.2 By Company, India Premature Ovarian Failure Cure Revenue Market Share, 2024
8.9.3 by Type, India Premature Ovarian Failure Cure Revenue Market Share, 2024 VS 2031
8.9.4 by Application, India Premature Ovarian Failure Cure Revenue Market Share, 2024 VS 2031
8.10 Middle East & Africa
8.10.1 Middle East & Africa Premature Ovarian Failure Cure Market Size, 2020-2031
8.10.2 By Company, Middle East & Africa Premature Ovarian Failure Cure Revenue Market Share, 2024
8.10.3 by Type, Middle East & Africa Premature Ovarian Failure Cure Revenue Market Share, 2024 VS 2031
8.10.4 by Application, Middle East & Africa Premature Ovarian Failure Cure Revenue Market Share, 2024 VS 2031

9 Company Profile
9.1 Pfizer
9.1.1 Pfizer Company Information, Head Office, Market Area, and Industry Position
9.1.2 Pfizer Company Profile and Main Business
9.1.3 Pfizer Premature Ovarian Failure Cure Models, Specifications, and Application
9.1.4 Pfizer Premature Ovarian Failure Cure Revenue and Gross Margin, 2020-2025
9.1.5 Pfizer Recent Developments
9.2 Bayer
9.2.1 Bayer Company Information, Head Office, Market Area, and Industry Position
9.2.2 Bayer Company Profile and Main Business
9.2.3 Bayer Premature Ovarian Failure Cure Models, Specifications, and Application
9.2.4 Bayer Premature Ovarian Failure Cure Revenue and Gross Margin, 2020-2025
9.2.5 Bayer Recent Developments
9.3 Novartis
9.3.1 Novartis Company Information, Head Office, Market Area, and Industry Position
9.3.2 Novartis Company Profile and Main Business
9.3.3 Novartis Premature Ovarian Failure Cure Models, Specifications, and Application
9.3.4 Novartis Premature Ovarian Failure Cure Revenue and Gross Margin, 2020-2025
9.3.5 Novartis Recent Developments
9.4 Bioscience Institute
9.4.1 Bioscience Institute Company Information, Head Office, Market Area, and Industry Position
9.4.2 Bioscience Institute Company Profile and Main Business
9.4.3 Bioscience Institute Premature Ovarian Failure Cure Models, Specifications, and Application
9.4.4 Bioscience Institute Premature Ovarian Failure Cure Revenue and Gross Margin, 2020-2025
9.4.5 Bioscience Institute Recent Developments
9.5 Johns Hopkins Medicine
9.5.1 Johns Hopkins Medicine Company Information, Head Office, Market Area, and Industry Position
9.5.2 Johns Hopkins Medicine Company Profile and Main Business
9.5.3 Johns Hopkins Medicine Premature Ovarian Failure Cure Models, Specifications, and Application
9.5.4 Johns Hopkins Medicine Premature Ovarian Failure Cure Revenue and Gross Margin, 2020-2025
9.5.5 Johns Hopkins Medicine Recent Developments
9.6 Mayo Clinic
9.6.1 Mayo Clinic Company Information, Head Office, Market Area, and Industry Position
9.6.2 Mayo Clinic Company Profile and Main Business
9.6.3 Mayo Clinic Premature Ovarian Failure Cure Models, Specifications, and Application
9.6.4 Mayo Clinic Premature Ovarian Failure Cure Revenue and Gross Margin, 2020-2025
9.6.5 Mayo Clinic Recent Developments
9.7 Baptist Health
9.7.1 Baptist Health Company Information, Head Office, Market Area, and Industry Position
9.7.2 Baptist Health Company Profile and Main Business
9.7.3 Baptist Health Premature Ovarian Failure Cure Models, Specifications, and Application
9.7.4 Baptist Health Premature Ovarian Failure Cure Revenue and Gross Margin, 2020-2025
9.7.5 Baptist Health Recent Developments
9.8 Indira IVF
9.8.1 Indira IVF Company Information, Head Office, Market Area, and Industry Position
9.8.2 Indira IVF Company Profile and Main Business
9.8.3 Indira IVF Premature Ovarian Failure Cure Models, Specifications, and Application
9.8.4 Indira IVF Premature Ovarian Failure Cure Revenue and Gross Margin, 2020-2025
9.8.5 Indira IVF Recent Developments

10 Conclusion

11 Appendix
11.1 Research Methodology
11.2 Data Source
11.2.1 Secondary Sources
11.2.2 Primary Sources
11.3 Market Estimation Model
11.4 Disclaimer

According to YH Research, the global market for Premature Ovarian Failure Cure should grow from US$ 1085 million in 2024 to US$ 1755 million by 2031, with a CAGR of 7.2% for the period of 2025-2031.

Premature ovarian failure (POF, also called primary ovarian insufficiency or early menopause) is a common gynecological endocrine disease characterized by the loss of ovarian function in women below 40 years. Most often, it is a non-reversible pathology leading to infertility. Normally, ovaries produce hormones and eggs until the early fifties, when they stop working and most women enter menopause. However, phenomena such as the dysfunction and the depletion of follicles (the cellular aggregates in the ovaries secreting hormones that influence the menstrual cycle) lead to POF, whose prevalence is 1/250 in women under 35 years and 1/100 in women under 40 years; the consequent loss of ovarian reserve (the number of follicles remaining in a woman’s ovaries) increases the risk of infertility, severely affecting women both physically and mentally.

Premature Ovarian Failure Cure

According to YH Research, the global market for Premature Ovarian Failure Cure should grow from US$ 1085 million in 2024 to US$ 1755 million by 2031, with a CAGR of 7.2% for the period of 2025-2031.

Unit: US$ M

www.yhresearch.com

In-depth insight into market trends

Pfizer and Bayer are the top two manufacturers of premature ovarian failure cure globally and account for over 30% of global market share in total. Geographically speaking, North America holds about 45% of global market share, followed by Asia-Pacific with over 25% share. Premature Ovarian Failure Cure method mainly includes Hormone Replacement Therapy (HRT), Calcium and Vitamin D Supplements, In Vitro Fertilization (IVF), Stem Cell Therapy. HRT is a common line of treatment for women with premature ovarian failure. The treatment is usually comprised of estrogen to replace hormones that the body is no longer making. Estrogen therapy also reduces the risk of stroke, heart attack, osteoporosis, and high blood pressure. Evidence regarding the risks associated with HRT in the treatment of premature menopause is limited. Hormone replacement therapy (HRT) segment holds an important share of about 50%. In terms of application, 20 to 30 years old holds over 45% of total market share.

This report aims to provide a comprehensive study of the global market for Premature Ovarian Failure Cure. Report Highlights:
(1) Global Premature Ovarian Failure Cure market size (value), history data from 2020-2024, and forecast data from 2025 to 2031.

(2) Global Premature Ovarian Failure Cure market competitive situation, revenue, and market share, from 2020 to 2024.

(3) China Premature Ovarian Failure Cure market competitive situation, revenue, and market share, from 2020 to 2024.

(4) Global Premature Ovarian Failure Cure segment by region (or country), key regions cover the United States, Europe, China, Japan, South Korea, Southeast Asia, and India, etc.

(5) Global Premature Ovarian Failure Cure segment by Type, and by Application, and regional segment by Type, and by Application.

(6) Premature Ovarian Failure Cure industry supply chain, upstream, midstream, and downstream analysis.

Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa
Market segment by Type, covers
Hormone Replacement Therapy (HRT)
Calcium and Vitamin D Supplements
In Vitro Fertilization (IVF)
Stem Cell Therapy
Others

Market segment by Application, can be divided into
Less than 20 Years Old
20 to 30 Years Old
30 to 45 Years Old
45 Years Old and Older

Market segment by players, this report covers
Pfizer
Bayer
Novartis
Bioscience Institute
Johns Hopkins Medicine
Mayo Clinic
Baptist Health
Indira IVF